Doctors Note Logo

Published on: 9/24/2026

What are the latest treatments for type 1 diabetes?

The latest type 1 diabetes treatments include automated insulin delivery (hybrid closed-loop) systems that pair continuous glucose monitors with smart pumps, ultra-rapid and longer-acting insulin analogs, and teplizumab (Tzield), the first immunotherapy shown to delay the onset of stage 3 disease in people at risk. Emerging options such as stem cell derived islet cell transplants, adjunct medications like metformin or SGLT inhibitors, and next generation sensors are also expanding what is possible beyond insulin alone. Which approach fits depends on your antibody status, glucose patterns, hypoglycemia risk, and access to technology, so there are several important factors to consider below before deciding what to discuss with your care team.

If you are noticing symptoms like excessive thirst, frequent urination, unexplained weight loss, or fatigue, knowing where you stand matters more than any single treatment headline, because timing changes which therapies are even available to you. Take a free, instant, online symptom check to clarify what your symptoms may mean and get guidance on the right next steps.

Last reviewed for medical accuracy: 09/24/2026

answer background

Explanation

What Are the Latest Treatments for Type 1 Diabetes?

Type 1 diabetes (T1D) occurs when the body’s immune system destroys insulin-producing beta cells in the pancreas. Without insulin, blood sugar stays too high, leading over time to complications such as heart disease, nerve damage and kidney problems. While researchers have made important strides, there is currently no proven way to fully “cure” or reverse type 1 diabetes. That said, advances in insulin delivery, glucose monitoring, immune therapies and cell-replacement strategies are transforming day-to-day management—and bringing us closer to one day preventing or reversing the disease.

Can You Reverse Type 1 Diabetes?

“Can you reverse type 1 diabetes?” is one of the most common questions patients ask. At present:

  • There is no widely accepted therapy that restores your own insulin production permanently.
  • Early-stage clinical trials of immunotherapies (like anti-CD3 antibodies) have slowed down beta-cell loss in some participants, but haven’t fully reversed the disease.
  • Beta-cell replacement—through pancreas or islet transplantation—can restore insulin production, but requires lifelong immune suppression and is reserved for select cases.

In short, we cannot yet reverse type 1 diabetes in the way we might reverse prediabetes or type 2 diabetes through lifestyle alone. However, ongoing research brings hope that future treatments may rebuild or protect insulin-making cells.

Current Standard of Care

Managing T1D today focuses on replicating normal insulin patterns as closely as possible, plus constant glucose monitoring:

  1. Exogenous Insulin Therapy

    • Multiple daily injections (MDI) of long-acting (basal) and rapid-acting (bolus) insulin.
    • Insulin pump therapy delivers precise basal rates and boluses at mealtimes.
    • Implantable insulin pumps (in clinical use) can last several months without refill.
  2. Continuous Glucose Monitoring (CGM)

    • A tiny sensor under the skin measures glucose every 5–15 minutes.
    • Alerts warn you of highs and lows so you can correct with insulin, carbs or exercise.
    • Integration with pumps enables automatic insulin adjustments.
  3. Hybrid Closed-Loop Systems (“Artificial Pancreas”)

    • Connects a CGM to an insulin pump via an algorithm that adjusts insulin delivery in real time.
    • Major systems now available in many countries cut average blood sugar (A1C) by 0.5–1.0% and reduce low-sugar events.
    • Next-generation “full closed loop” devices aim for tighter control with no meal bolus required.

Emerging Immune and Cell-Based Therapies

Researchers are exploring ways to halt the autoimmune attack and rebuild insulin production.

• Immunotherapies

  • Anti-CD3 antibodies (e.g., teplizumab) have delayed clinical onset in high-risk individuals by preserving residual beta cells.
  • Trials of anti-TNF, anti-IL-21 and regulatory T-cell boosters aim to retrain the immune system to tolerate beta cells.
  • Combination approaches (immunomodulator + beta-cell growth factor) are under study.

• Beta-Cell Replacement

  • Islet Transplantation: Infusion of donor islet cells into the liver can free some patients from insulin injections. Limitations include donor scarcity and lifelong immune suppression.
  • Pancreas Transplant: Whole-organ transplant may be considered in people with kidney failure; it provides durable insulin independence but carries surgical risks.

• Encapsulation Technologies

  • Encapsulated islets are coated in a protective material that shields them from immune attack—potentially eliminating the need for systemic immunosuppression.
  • Early-phase clinical studies (ViaCyte, Sigilon) are testing different capsules and cell sources (human stem cells).

• Stem-Cell Derived Therapies

  • Human pluripotent stem cells can be coaxed into insulin-producing cells in the lab.
  • Implanted devices containing these cells are now in Phase I/II trials to evaluate safety and function.

• Gene and RNA-Based Strategies

  • Gene editing (CRISPR) to correct autoimmune triggers or engineer beta cells with “immune-evasive” properties.
  • mRNA technologies could one day deliver instructions to regrow beta cells in vivo.

Supporting Your Well-Being Today

While awaiting breakthroughs, focus on tools and habits that help you live your healthiest life:

• Personalized Nutrition

  • Carb counting remains central, but consider working with a registered dietitian to fine-tune meal timing and composition.
  • Low-glycemic meals and mindful eating can smooth out glucose swings.

• Physical Activity

  • Exercise enhances insulin sensitivity and cardiovascular health.
  • Monitor closely—activity can cause both low and high sugars depending on intensity and duration.

• Technology Adoption

  • Continuous glucose data can guide smarter insulin dosing, carb choices and exercise planning.
  • Smartphone apps, smart pens and connected scales help track patterns and share info with your care team.

• Mental Health & Support

  • Living with T1D can be stressful. Seek peer support groups or professional counseling to manage burnout and anxiety.
  • A strong support network makes a big difference in long-term success.

When to Check Symptoms Online

If you experience worrisome signs—such as unexplained high blood sugars, frequent hypos, extreme thirst or sudden weight loss—you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. This quick tool can help you decide whether to seek urgent care or schedule an appointment with your diabetes team.

Why Talking to Your Doctor Matters

Every person’s diabetes is unique. Before making any changes to medication, diet or exercise:

  • Discuss new technologies (pumps, CGMs, apps) with your endocrinologist or certified diabetes educator.
  • If you’re interested in a clinical trial—be it immunotherapy, transplant or stem-cell therapy—ask your doctor whether you qualify.
  • Report any severe high or low blood sugars, vision changes, foot wounds or other potentially serious issues right away.

Key Takeaways

  • Can you reverse type 1 diabetes? Not yet—but research in immunotherapy, encapsulation and stem cells offers hope.
  • Current best practice relies on insulin delivery (pumps or injections) plus continuous glucose monitoring and healthy lifestyle habits.
  • Emerging treatments aim to protect or replace beta cells, potentially one day reducing or eliminating the need for daily insulin.
  • Your role: Stay informed, embrace technology that fits your life and stay in close touch with your diabetes care team.

Always remember, managing T1D is a team effort—you, your healthcare providers and your support network. If you ever feel overwhelmed or notice serious symptoms, talk to a doctor right away. Continuous innovation is making this journey easier and safer every year, and one day we may finally answer “can you reverse type 1 diabetes” with a firm yes. Until then, the best path is proactive management, informed decisions and ongoing dialogue with your medical team.

(References)

  • * Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. 2015 Sep 1;70:5.47.1-5.47.20. doi: 10.1002/0471141755.ph0547s70. Epub 2015 Sep 1. PMID: 26331889.

  • * Sethuram S, Rapaport R. Update: Pediatric Diabetes. J Diabetes. 2020 Oct;12(10):769-771. doi: 10.1111/1753-0407.13033. Epub 2020 Mar 13. PMID: 32166876.

  • * Castellanos L, Tuffaha M, Koren D, Levitsky LL. Management of Diabetic Ketoacidosis in Children and Adolescents with Type 1 Diabetes Mellitus. Paediatr Drugs. 2020 Aug;22(4):357-367. doi: 10.1007/s40272-020-00397-0. PMID: 32449138.

  • * Kordonouri O, Kerner W. [Type 1 diabetes: an update]. Internist (Berl). 2021 Jun;62(6):627-637. doi: 10.1007/s00108-021-01009-w. Epub 2021 Apr 7. PMID: 33825933; PMCID: PMC8024935.

  • * Toschi E, Atakov-Castillo A, Slyne C, Munshi M. Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data. Diabetes Technol Ther. 2022 Feb;24(2):140-142. doi: 10.1089/dia.2021.0311. Epub 2021 Oct 28. PMID: 34609917; PMCID: PMC8817701.

  • * Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho CN, Ayers AT, Tian T, Aaron RE, Klonoff DC. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. J Diabetes Sci Technol. 2025 Jan;19(1):191-216. doi: 10.1177/19322968241291512. Epub 2024 Nov 8. PMID: 39517127; PMCID: PMC11571606.

  • * Ebrahimpour Y, Khatami S, Saffar M, Fereidouni A, Biniaz Z, Erfanian N, Fereidouni M. A Comprehensive Review of Novel Advances in Type 1 Diabetes Mellitus. J Diabetes. 2025 Aug;17(8):e70120. doi: 10.1111/1753-0407.70120. PMID: 40765373; PMCID: PMC12326085.

  • * Jerram ST, Yang JHM, Williams E, Domingo-Vila C, Liu YF, Peakman M, Leslie RD, Tree T. Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects. Diabetes Metab Res Rev. 2025 Sep;41(6):e70074. doi: 10.1002/dmrr.70074. PMID: 40790833; PMCID: PMC12340168.

  • * Ziegler AG, Cengiz E, Kay TWH. The future of type 1 diabetes therapy. Lancet. 2025 Oct 4;406(10511):1520-1534. doi: 10.1016/S0140-6736(25)01438-2. Epub 2025 Sep 19. PMID: 40983070.

  • * You L, Parikh HM, Triolo TM, Ferrat LA, Templeman EL, Oram RA, Gottlieb PA, Rich SS, Onengut-Gumuscu S, Steck AK, Krischer J, Redondo MJ. Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention. Diabetes Care. 2026 Feb 1;49(2):344-351. doi: 10.2337/dc25-2006. PMID: 41364459; PMCID: PMC12824796.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.